Financial Performance - Marker Therapeutics reported a net loss of 4.1 million in Q2 2023, reflecting improved financial performance[7] - Total revenues for June 2024 were 762,658 in June 2023[14] - Loss from operations improved to (4,134,060) in June 2023, a decrease of 44.2%[14] - Net loss from continuing operations for June 2024 was (8,323,807) in June 2023, reflecting a 44.0% improvement[16] Expenses - Research and development expenses for Q2 2024 were 2.4 million in the same quarter last year[7] - General and administrative expenses decreased significantly to 2.5 million in Q2 2023[7] - Total operating expenses decreased to 4,896,718 in June 2023, representing a reduction of 29.0%[14] - Research and development expenses were 2,377,993 in June 2023[14] - General and administrative expenses significantly decreased to 2,518,725 in June 2023, a reduction of 54.7%[14] Cash Position - The company had cash and cash equivalents of 7,800,464, a decrease from (7,404,688), compared to 2 million grant from the NIH to support the clinical investigation of MT-601 in patients with lymphoma[4] - The FDA cleared the IND application for MT-601 to be investigated in combination with front-line chemotherapy for metastatic pancreatic cancer[5] - The company is enrolling additional participants in the Phase 1 APOLLO trial and expects to provide updates on safety and durability in Q3 2024[4] - Marker Therapeutics has established a cellular inventory for MT-401-OTS, which is intended for patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome[5] Stockholders' Equity - Total stockholders' equity decreased to 14.1 million at the end of 2023[13] Other Financial Metrics - Interest income increased to 35,080 in June 2023, marking a growth of 228.3%[14] - The weighted average number of common shares outstanding was 8,918,233 in June 2024, compared to 8,798,956 in June 2023, an increase of 1.4%[14]
Marker Therapeutics(MRKR) - 2024 Q2 - Quarterly Results